Thomas M Suter

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

M. Dowsett, R. Gelber, J. Baselga, 2013, The Lancet.

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

A. Goldhirsch, C. Criscitiello, G. Curigliano, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.

T. Suter, C. Barton, N. Cook-Bruns, 2004, Breast.

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

J. Baselga, T. Suter, D. Lenihan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.